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Abstract
The excitotoxin quinolinic acid (QUIN) is synthesized through the kynurenine pathway (KP) by
activated monocyte lineage cells. QUIN is likely to play a role in the pathogenesis of several major
neuroinflammatory diseases including Alzheimer's disease (AD). The presence of reactive
astrocytes, astrogliosis, increased oxidative stress and inflammatory cytokines are important
pathological hallmarks of AD. We assessed the stimulatory effects of QUIN at low physiological to
high excitotoxic concentrations in comparison with the cytokines commonly associated with AD
including IFN-γ and TNF-α on primary human astrocytes. We found that QUIN induces IL-1β
expression, a key mediator in AD pathogenesis, in human astrocytes. We also explored the effect
of QUIN on astrocyte morphology and functions. At low concentrations, QUIN treatment induced
concomitantly a marked increase in glial fibrillary acid protein levels and reduction in vimentin levels
compared to controls; features consistent with astrogliosis. At pathophysiological concentrations
QUIN induced a switch between structural protein expressions in a dose dependent manner,
increasing VIM and concomitantly decreasing GFAP expression. Glutamine synthetase (GS) activity
was used as a functional metabolic test for astrocytes. We found a significant dose-dependent
reduction in GS activity following QUIN treatment. All together, this study showed that QUIN is
an important factor for astroglial activation, dysregulation and cell death with potential relevance
to AD and other neuroinflammatory diseases.
Background
In physiological conditions, the kynurenine pathway (KP)
catabolises the essential amino acid L-tryptophan (L-TRP)
to nicotinamide adenine dinucleotide (NAD+). During
inflammation, the KP can be activated by cytokines and
more particularly interferon-γ (IFN-γ) leading to the pro-
duction of quinolinic acid (QUIN) by monocyte lineage
cells. QUIN is an endogenous competitive agonist of the
N-methyl-D-aspartate (NMDA) receptor, acting specifi-
cally on the subgroup containing the NR2A and NR2B
subunits [1,2]. QUIN neurotoxicity has been shown to be
involved in the pathogenesis of several age-related neuro-
degenerative processes associated with neuroinflamma-
tion including Alzheimer's disease (AD) [3-6]. Earlier
studies with animal models have found that QUIN levels
increase with age in the cortex of rats [7]. The neural dam-
age caused by QUIN is similar to the pathologic character-
istics of age related-AD [8]. Interestingly QUIN shares
several mechanisms with amyloid beta (Aβ) in terms of
neurotoxicity and neuroinflammation (Table 1).
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Alterations of the functionality of glial cells, including
changes in morphology and proliferative activity, are a
common feature of neuroinflammation [9]. Microglia
represent the major immune cell type within the brain.
When activated, they target foreign molecules including
amyloid plaques, and secrete cytokines, free radicals, and
other cytotoxic substances that rapidly become neurotoxic
[10]. Activated microglia are the major source of QUIN
during brain inflammation [11]. We previously showed
that activated microglia surrounding the amyloid plaque
are highly immunoreactive for QUIN [5]. Astrocytes are
also involved in the glial response during neuroinflamma-
tion and closely interact with microglia [12]. The presence
of reactive astrocytes is a known feature of AD pathology.
Astrogliosis with increased vimentin (VIM) and decreased
glial fibrillary acidic protein (GFAP) expression, and
marked elevations in inflammatory, immune, and oxida-
tive stress markers, extracellular matrix molecules, and
cytokines are also common features of AD [13,14]. We
previously showed that QUIN up-regulates chemokine
production and chemokine receptor expression in pri-
mary human astrocytes [15]. Moreover, low doses of
QUIN or IL-1β alone do not have significant deleterious
effects but in combination lead to a significant loss of
pyramidal neurons in the rat hippocampus [16]. How-
ever, it still remains unknown whether QUIN production
from Aβ-activated microglia can directly induce produc-
tion of pro-inflammatory cytokines by astrocytes. We pre-
viously demonstrated that 500 and 1200 nM QUIN
induces apoptosis in human foetal astrocytes (10 and
15%, respectively) [17]. To our knowledge, the effects of
QUIN on astrocyte proliferation, cytokine production and
enzymatic functions have not been studied. Moreover, it
is unknown whether low sub-toxic doses of QUIN would
potentially have proliferative and/or apoptotic effects on
human astrocytes. To further examine this, we focused on
the expression of cytoskeleton proteins (GFAP and VIM)
and astrocyte proliferation as it is plausible that in addi-
tion to apoptosis by QUIN, the remaining 85 to 95% of
live astrocytes may undergo astrogliosis (hypertrophy) or
astrocytosis (hypertrophy and proliferation). Addition-
ally, neuronal activity leads to production of glutamate,
which is then taken up by astrocytes, via Na+ -dependent
glutamate transporters, and recycled to glutamine [18].
The regulatory enzyme of the glutamate-glutamine cycle
in astrocytes is glutamine synthetase (GS). GS inhibition
has been previously described in AD pathogenesis [19].
The present study was designed to determine: 1) the effect
of QUIN on human primary astrocytes in the expression
of AD-related pro-inflammatory cytokines, 2) the ability
of QUIN to activate astrocytes and induce their prolifera-
tion at lower doses and 3) to investigate the effect of
increasing doses of QUIN on GS activity as a functionality
test. Understanding the effects of QUIN on human astro-
cytes is essential to better understand the neuroinflamma-
Table 1: Summary of the effects of QUIN in comparison with Aβ mediated toxicity
QUIN toxicity References Aβ toxicity References
• Free radical production via 
over-activation of NMDA 
receptor and/or QUIN-Fe2+ 
complexes and consequent lipid 
peroxidation and cell death.
(Platenik et al., 2001) (Stone and 
Perkins, 1981)
￿ Free radical production via 
Fenton reaction by metals Cu and 
Fe and consequent lipid 
peroxidation and apoptosis.
(Huang et al., 1999) (Varadarajan 
et al., 2001) (Markesbery and 
Lovell, 1998) 
(Tamaoka et al., 2000)
￿ Excessive PARP activation 
leading to NAD depletion.
(Maldonado et al., 2007) ￿ DNA damage by ROS leads to 
PARP over-activation and 
NAD depletion.
(Meyer et al., 2006) (Love et al., 
1999)
￿ Activation of astrocytes 
including release of inflammatory 
chemokines and astrogliosis.
(Guillemin et al., 2003b) (Dihne et 
al., 2001) (Hanbury et al., 2002)
￿ Activation of microglia and 
other immune cells leading to 
secretion of inflammatory 
cytokines and proteins.
￿ Co-activation of astrocytes 
by inflammatory factors leading to 
further release of cytokines and 
astrogliosis.
Griffin and Mrak, 2002) (Murphy et 
al., 1998) (Selmaj et al., 1990)
￿ Inhibition of glutamate 
uptake leading to excitotoxicity.
(Tavares et al., 2002) ￿ Aβ can increase extracellular 
glutamate resulting in NMDA 
receptor over-activation and 
excitotoxicity.
(Lafon-Cazal et al., 1993; Keller et 
al., 1997; Lauderback et al., 2001) 
(Harris et al., 1995; Harris et al., 
1996)
￿ NMDA receptor activation by 
QUIN can lead to Aβ production.
(Lesne et al., 2005) ￿ Aβ can induce IDO in the KP and 
increase production of QUIN.
(Guillemin et al., 2003a)Journal of Neuroinflammation 2009, 6:36 http://www.jneuroinflammation.com/content/6/1/36
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tory mechanisms involved in AD and other
neuroinflammatory diseases and to facilitate the develop-
ment of new therapeutic targets for neurodegenerative dis-
eases [20].
Materials and methods
Reagents
Cell culture
Dulbecco's phosphate buffered saline (PBS) 1×, RPMI
medium 1640 1×, 0.5% Trypsin-EDTA 10×, Glutamax-1
100×, Antibiotic-Antimycotic (AA) 100× were obtained
from GIBCO Invitrogen (Victoria, Australia). Glucose
intravenous infusion BP 50% was from AstraZeneca (Syd-
ney, Australia). Foetal calf serum (FCS) was obtained
from Bovogen Australia. Culture flasks and plates were
purchased from Becton Dickinson labware (New Jersey,
USA). Recombinant human IFN-γ, recombinant TNF-α
and TGF-α were from RnD Systems. Quinolinic acid
(QUIN) was obtained from Sigma Chemical (Sydney,
Australia).
PCR and electrophoresis
Rneasy Mini Kit and Q solution were obtained from QIA-
GEN (Victoria, Australia). Buffer 10× 1.5 mM, Taq
polymerase, dNTP 10 mM were obtained from Roche
(Sydney, Australia). Accuprime PCR system and cyto-9
fluorescence dye were purchased from Invitrogen. PCR
primers were purchased from Geneworks (South Aus-
tralia, Australia). Agarose 1 biotechnology grade powder
was obtained from Amresco (Ohio, USA).
End Point PCR reaction per tube (100  L)
10 μL Buffer 10× pre-mixed with MgCl2 1.5 mM + 2.5 μL
dNTP 10 mM + 1 μL (10 μM) Forward primer + 1 μL (10
μM) Reverse primer + 0.5 μL Taq Polymerase + 80 μL
DEPC H2O + 5 μL sample cDNA.
Real-time PCR reaction per tube (20  L)
2 μL Buffer 10× pre-mixed with MgCl2 3 mM + 0.4 μL
dNTP 10 mM+3 μL Q solution + 0.2 μL SybrGreen
(1:1000), 0.2 μL Taq Polymerase + 0.2 μL (10 μM) for-
ward and reverse primer + 9 μL H2O + 5 μL diluted sample
cDNA (1 part stock cDNA in 4 parts of nuclease-free H2O)
GFAP and vimentin enzyme linked immunosorbent assay (ELISA)
Human GFAP ELISA kit was obtained from Biovendor
Laboratory Medicine, Inc. (Modrice, Czech Republic). As
there are no commercial ELISA kits for vimentin, an indi-
rect vimentin ELISA protocol was generated. Primary
monoclonal mouse vimentin antibody (0.5 mg/mL) used
in the ELISA was purchased from BD Pharmingen (Cali-
fornia, USA). Secondary goat anti-mouse antibodies con-
jugated with horseradish peroxidise (0.5 mg) were
obtained from Novus Biologicals (Littleton, USA). The
coating buffer consisted of 3.03 g Na2CO3, 6 g NaHCO3
from Lancaster (Morecambe, England) in 1 litre (L) dH2O
(pH 9.6). 3,3'5, 5'-Tetramethylbenzidine (TMB) liquid
substrate system for ELISA (ready to use), bovine serum
albumin (BSA) (pH 7), and 0.05% PBS-tween (PBS-T)
were purchased from Sigma Aldrich (Sydney, Australia).
Wash solution was made up of 0.05% PBS-tween. Stop
solution composed of 2 N sulfuric acid (H2SO4) was used
in both GFAP and vimentin ELISA. NUNC maxisorp flat
bottom ELISA plates (New York, USA) were used for the
vimentin ELISA study. Samples were sonicated in PBS sup-
plemented with 1× EDTA-free "complete" cocktail of pro-
tease inhibitors purchased from Roche Diagnostics
(Mannheim, Germany).
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay
MTT was obtained from Sigma Chemical. Sodium
dodecyl sulfate (SDS) was sourced from International Bio-
technologies Inc (Connecticut, USA) and N, N-dimethyl-
formamide (DMF) from Ajax Chemicals (Auburn,
Australia).
Glutamine synthetase activity assay
Lysis buffer
HEPES (20 mM), NaCl (118 mM), KCl (4.6 mM),
KH2PO4 (1.1 mM), MgCl2 (1.2 mM) and 1× Complete-
EDTA free inhibitors.
Reaction buffer
Imidazole-HCl (50 mM, pH 7.2), KH2AsO4 (25 mM),
hydroxylamine/NH2OH (50 mM), L-glutamine (50
mM), MnCl2  (0.5 mM), Adenosine 5'-diphosphate
sodium salt (ADP) (0.4 mM).
Stop solution
FeCl3 (0.37 M), hydrochloric acid (HCl) (0.67 M) and
trichloroacetic acid (TCA) (0.2 M).
Chemicals
HEPES from JRH Biosciences (Kansas, USA), NaCl from
Merck, KCl, hydroxylamine/NH2OH, L-glutamine, ADP,
FeCl3 and KH2AsO4 from Sigma Chemicals (Sydney, Aus-
tralia), KH2PO4, MgCl2 from Ajax Chemicals and 1× Com-
plete-EDTA free inhibitors from Roche Diagnostics.
Imidazole-HCL from Aldrich Chemical Company, Inc.
(Milwaukee, USA), Tri-Sodium Citrate, HCl and TCA
from Ajax Chemicals and MnCl2 from BDH Chemicals Ltd
(Poole, England). GS activity was measured using the
Cary 50BIO UV spectrophotometer (Varian, Sydney).
Cell culture conditions and cell lines
All cells were maintained at 37°C under 5% CO2 in
humidified air. U251 glioblastoma is a malignant cell line
derived from human glia and was obtained from Ameri-
can Type Culture Collection (ATCC). It was used as a pos-Journal of Neuroinflammation 2009, 6:36 http://www.jneuroinflammation.com/content/6/1/36
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itive control for vimentin and GFAP expression and was
cultured in Dulbecco's RPMI medium 1640 supple-
mented with 10% FCS, 1% glutamax-1, 1% AA and 0.5%
glucose.
Methods
Isolation and culture of primary astrocytes
Human foetal brains were obtained from 18- to 19-week-
old foetuses following informed consent. Astrocytes were
prepared using a previously described protocol [21].
Briefly, cerebral portions were washed thoroughly with
phosphate-buffered saline (PBS), forced through a 100
μm nylon mesh with the plunger of a plastic syringe. The
suspension was centrifuged at 500 g for 5 minutes and the
cell pellet resuspended in RPMI 1640 medium containing
10% heat-inactivated FCS, 1% glutamax-1, 1% antibiotic-
antimicrobial liquid, 0.5% glucose, then plated onto 75
cm2 culture flasks and incubated at 37°C. Medium was
changed on the 3rd, 5th and 10th day. The cells became con-
fluent after 10-12 days. Microglia were detached from the
cultures by mechanically shaking the flasks for 2 hours at
220 rpm at room temperature and aspirated. The astro-
cytes were passaged at least three times to further purify
and isolate astrocytes from contaminating microglia and
neurons. Astrocytes were left to recover for 3 days after
each passage. The astrocytes were rinsed twice with PBS
and cultured as above in uncoated flasks with the culture
medium and maintained for up to 6 weeks. The medium
was changed twice a week. Culture purity was determined
by immunofluorescence analysis with antibodies against
GFAP and more than 95% of the cells stained positive for
GFAP [22].
Purified astrocytes were subcultured into 12-well plates
and left to recover for 48 hours. For the real-time PCR
experiments, the astrocytes were treated with IFN-γ (100
IU/mL), TNF-α (100 IU/mL), TGF-α (20 ng/μL) and
QUIN (50, 150, 350, 500 and 1200 nM) and incubated
for 24 hr at 37°C unless otherwise stated.
RNA extraction and first strand cDNA synthesis
Astrocytes were washed twice with PBS before extraction.
RNA extraction was performed based on the protocol
stated by QIAGEN for Rneasy mini kit. Each RNA stock
sample was diluted 1:10 and mixed thoroughly, spun
down and kept on ice. An RNA standard derived from
liver tissue (50 ng/μL) was diluted 1:10 to make standards
of 10, 20, 30, 40, 50, 60 ng. Each diluted RNA sample was
added into 96-well plates at volumes of 3 μL and 7 μL.
Next, a stock solution of TE buffer (10×) was diluted to 1×
and 0.1 μL SYBRgreen II dye was added to each mL of TE
buffer. Finally, 0.2 mL of 1× TE-SYBRgreen II buffer was
added into each well of standard and samples. Blank wells
contained no samples nor standards, only 1× TE-
SYBRgreen II buffer. Fluorescence intensity for the stand-
ard and the samples was measured using FLUOstar
Optima fluorometer machine (BMG Labtech, Victoria,
Australia). A standard curve was formed and RNA concen-
tration was determined from the standard curve equation.
cDNA synthesis was performed based on the protocol
stated by Invitrogen for RT-PCR system using Thermo-
Script™. For each sample, 0.5 μg RNA was used for the
cDNA synthesis.
End-point and real-time PCR
End-point PCR conditions for all primers were: denatura-
tion at 94°C for 1.5 minutes, annealing at 60°C for 30
seconds, followed by extension at 72°C for 60 seconds.
All end-point PCR was done in 35 cycles using an Eppen-
dorf thermocycler. The purpose of end-point PCR was to
screen semi-quantitatively for the presence of the follow-
ing genes in primary human foetal astrocytes.
Standards of cDNA for β-actin, vimentin, GFAP and IL-1β
to be used for quantitative measure in real-time PCR were
synthesized using the double end-point PCR method that
utilizes real-time PCR conditions. Briefly, 5 μL of stock
cDNA for each gene of interest was mixed with 15 μL mas-
ter mix in duplicates and end-point PCR of 45 cycles was
performed. PCR products were analysed on the agarose
gel for correct product size. Next, add 5 μL of 1st PCR aliq-
uot to 15 μL of 2nd PCR master mix in duplicates and a 2nd
end-point PCR is performed with the same condition and
cycles as the 1st end-point PCR. At this step, both duplicate
tubes for each standard are mixed together to make a total
volume of 40 μL and loaded on to agarose gel for electro-
phoresis. The product bands for each standard should be
significantly thicker when viewed with UV illuminator.
The product bands for each standard are then cut and
extracted using QIAGEN gel extraction kit according to
manufacturer's protocol. Each PCR standard concentra-
tion was measured using the previously described method
for determining RNA concentration with the exception of
using SybrGreen dye I which is specific to detect cDNA.
After measuring the concentration, the standards were
diluted to a stock concentration of 10 ng/μL. Before per-
forming the real-time PCR, the standards were serial
diluted from the stock 1 in 10. Finally, the standards were
mixed with the master mix that was used for the samples
and loaded into the machine to amplify. A standard curve
can be generated from the values given and the unknown
concentration of each amplified sample can be deter-
mined.
Table 2 shows the PCR primer sequences used for real-
time PCR. PCR conditions for β-actin, vimentin and IL-1β:
denaturation (HOLD) at 95°C for 5 minutes then dena-
turation starts at 95°C for 10 seconds, annealing at 60°C
for 15 seconds, extension at 72°C for 15 seconds, fol-
lowed by a melt up to 99°C. β-Actin, vimentin and IL-1βJournal of Neuroinflammation 2009, 6:36 http://www.jneuroinflammation.com/content/6/1/36
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real-time PCR was done in 40-45 cycles. PCR conditions
for GFAP: denaturation (HOLD) at 94°C for 3 minutes
then denaturation starts at 94°C for 10 seconds, anneal-
ing at 58°C for 15 seconds, extension at 68°C for 30 sec-
onds, followed by a melt up to 99°C. GFAP real-time PCR
was done in 40 cycles. All real-time PCR was carried out in
triplicates using Corbett Lightcycler, n = 3. Concentrations
of each samples and controls for β-Actin, vimentin, GFAP
and IL-1β were calculated from their respective standard
curve. Subsequently, we normalized the concentration
values of samples and controls found for vimentin, GFAP
and IL-1β with their respective β-Actin values to rule out
any differences in load between samples and controls.
Normalized untreated controls are then calculated as
100% and the percentage of samples was calculated rela-
tive to their controls. For example, a sample percentage of
180 would be calculated as 80% increase above controls.
After calculating the percentages of each samples and con-
trols, these percentages (in triplicates) are put together
with the values of 2 other triplicates derived from 2 inde-
pendent PCRs and the standard deviation and p-values
are determined using PRISM.
Electrophoresis
All PCR products were then loaded into 2% Agarose gels
supplemented with 0.001% ethidium bromide (EtBr).
Gel electrophoresis was carried out at 100 V for 40 min-
utes and analysed using Syngene UV illuminator machine.
GFAP ELISA
Human foetal astrocytes were plated onto 12-well plates
and grown until 90% confluent in RPMI with 10% FCS
overnight. The cells were stimulated with IFN-γ, TNF-α,
TGF-α and QUIN at 50, 150, 350, 500 and 1200 nM for
24 hrs. Cells were harvested by Trypsin/EDTA, centrifuged
at 13,000 rpm, aspirated and re-suspended in PBS. After
that, the cells were centrifuged at the same speed to form
a pellet at the bottom of the Eppendorf tube and soni-
cated to lyse the cells. The final volume of each sample
was 300 μL. ELISAs for GFAP were carried out according
to Biovendor human GFAP ELISA kit protocol. First, pre-
pare human GFAP standards according to manufacturer's
dilutions for duplicates. Next, dilute 100 μL of each sam-
ples with 200 μL dilution buffer provided by the kit. 100
μL of each standard and samples were added in duplicates
and incubated for 2 hours at room temperature. Next,
each well was washed 3 times with 350 μL wash solution
and after the final wash; the plate was inverted and tapped
strongly on paper towel. 100-μL biotin labelled anti-
human GFAP polyclonal antibody was added into each
well. Immunoreaction was allowed to proceed for 1 hour
at room temperature. The plates were then washed 3 times
as before and 100 μL streptavidin-horseradish peroxidase
conjugate was added to each well and incubated for 1
hour at room temperature. The plates were washed as pre-
viously stated followed by the addition of 100 μL tetram-
ethylbenzidine/hydrogen peroxide substrate solution and
incubated for 30 minutes covered with foil. The colour
Table 2: PCR primer sequences
End-point PCR Primers Forward Reverse Size (bp)
GAPDH ACCACCATGGAGAAGGCTGG CTCAGTGTAGCCCAGGATGC 509
IL-1β ATG GCAGAAGTACCTGAGCTC TTAGGAAGACACAAATTGCATGGTGAA 810
IL-6 GTGTGAAAGCAGCAAAGAGGC CTGGAGGTACTCTAGGTATAC 159
GFAP CTGGGCTCAAGCAGTCTACC CTGGGGTTAAGAAGCAGCAG 666
GS AAGTGTGTGGAAGAGTTGCC TGCTCACCATGTCCATTATC 234
S100β ATGTCTGAGCTGGAGAAGG CTGTCTGCTTTCTTGCATG 415
Real-time PCR Primers Forward Reverse Size (bp)
β-actin TCACCCACACTGTGCCCATCTACGA CAGCGGAACCGCTCATTGCCAATGG 295
Vimentin GAGAACTTTGCCGTTGAAGC TCCAGCAGCTTCCTGTAGGT 170
IL1β AAGGCGGCCAGGATATAACT CCCTAGGGATTGAGTCCACA 102
GFAP TCTCTCGGAGTATCTGGGAACTG TTCCCTTTCCTGTCTGAGTCTCA 81Journal of Neuroinflammation 2009, 6:36 http://www.jneuroinflammation.com/content/6/1/36
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development was stopped with stop solution and the
absorbance was read at 450 nm.
Direct vimentin ELISA
The direct vimentin ELISA method was modified from
Zeisberg et al [23]. Human foetal astrocytes were cultured
and stimulated as described above. Cells were harvested
by Trypsin/EDTA, centrifuged at 13,000 rpm, aspirated
and re-suspended in PBS. After that, the cells were centri-
fuged at the same speed to form a pellet at the bottom of
the Eppendorf tube and sonicated to lyse the cells. Stand-
ards were performed in duplicates and include using
U251 cells at different cell densities 8 × 105, 7 × 105, 6 ×
105, 5 × 105, 4 × 105, 3 × 105, 2 × 105, 1 × 105 per well.
ELISA plates were coated overnight (4°C) with a constant
cell density of 4 × 105 cell lysates or standards in coating
buffer. Wells were aspirated and washed 3 times with 300
μL wash buffer per well. After the last wash, the plate was
inverted and blotted on absorbent paper to remove resid-
ual buffer. Plates were blocked with 200 μL blocking solu-
tion (1% BSA in PBS) per well and incubated at room
temperature for 1 hour. Each well was aspirated and
washed 3 times with 300 μL wash buffer per well. 100 μL
of monoclonal mouse Vimentin primary antibody
(1:500) diluted in incubation buffer was added into each
well and incubated for 1 hour at room temperature. After
primary incubation, each well was aspirated and washed
with 300 μL wash buffer 5 times. 100 μL whole mouse IgG
HRP conjugated secondary antibody (1:1000) in incuba-
tion buffer was added into each well and incubated for 1
hour at room temperature. Next, all the wells were aspi-
rated and washed 5 times. Then into each well, 100 μL of
TMB was added as substrate for HRP resulting in a blue
colour formation in each well over a 30 minutes incuba-
tion period. Finally, adding 100 μL stop solution into
each well stopped the reaction resulting in yellow colour
development. The plate was measured using an ELISA
microplate reader at a wavelength of 450 nm. Sample and
standard absorbance were corrected with blank absorb-
ance. VIM protein levels were estimated as a relative value
from the standard curve and graphed as a percentage of
controls.
MTT cell viability/proliferation assay
Human foetal astrocytes were subcultured into 96-well
plates with a density of 5 × 103 cells per well. Serum-free,
5% FBS and 10% FBS supplemented normal RPMI 1640
medium were used as negative, normal and positive con-
trols, respectively to maintain astrocyte culture. TGF-α
was omitted, as 10% FBS was used as positive control in
this assay, even though TGF-α is a known inducer of GFAP
expression and astrogliosis [24]. IFN-γ, TNF-α (100 IU/
mL) and QUIN at 50, 150, 350, 500 and 1200 nM were
added to the astrocytes in 5% FBS supplemented normal
RPMI medium. The astrocytes were incubated for 24, 48,
72 and 96 hours. This MTT assay is a modified version
from the original protocol by [25]. This colorimetric assay
is based on the ability of a mitochondrial dehydrogenase
enzyme from viable cells to cleave the tetrazolium rings of
the pale yellow MTT and form dark blue formazan crystals
which are largely impermeable to cell membranes, thus
resulting in their accumulation within healthy cells. At
each time point, 20 μL of stock MTT (5 mg/mL) was
added into each well containing 0.4 mL of appropriate
medium and incubated for 4 hours at 37°C. Next, all
media was aspirated from each well and 20% SDS in 50%
DMF was added into all wells to solubilise the dark blue
formazan crystal product overnight at 37°C. The plates
were measured using BioRad Multiskan spectrometer at a
wavelength of 560 nm and 620 nm as reference. The
number of surviving cells is directly proportional to the
level of the formazan product created.
Glutamine Synthetase (GS) activity in "transferase" 
reaction
ADP+L-Glutamine+NH2OH→γ-glutamyl hydroxamate
The GS transferase reaction assay was adapted from
Thorndike and Reif-Lehrer [26]. Human foetal astrocytes
were seeded into 12-well plates until confluent with a
final density of 5 × 103 cells per well. The cells were then
stimulated with appropriate concentrations of QUIN and
incubated for 24 hours at 37°C. Afterwards, the cells were
rinsed twice with ice cold PBS. Next, 0.35 mL lysis buffer
was added to each well and sonicated and the lysates were
collected in Eppendorf tubes. The lysates were centrifuged
at 13,000 rpm for 5 minutes and supernatants transferred
to new Eppendorf tubes. All samples were kept on ice at
all times until the start of assay. Then, 0.1 mL of each sam-
ple supernatant was mixed with 0.4 mL of dH2O and 0.5
mL of reaction buffer to make a final volume of 1 mL in a
UV glass cuvette. The enzyme reaction and kinetics were
measured at 37°C for 15 minutes and the absorbance was
taken at wavelength of 340 nm at 0.1 seconds interval
using a Cary 50BIO UV spectrophotometer. GS activity
was measured only in the linear region of the kinetic curve
and calculated as Δ absorbance per minute. Changes in
the rate of GS activity between controls and samples were
calculated and graphed in percentage values.
Statistical analysis
Each experiment was repeated 3 independent times
which, included triplicates of each sample and controls.
All data from each experimental study was analysed using
the statistics software PRISM and unpaired student's t-test
was used to compare each treated samples with the
untreated controls. P values of less than 0.05 (p < 0.05)
was taken as significant.Journal of Neuroinflammation 2009, 6:36 http://www.jneuroinflammation.com/content/6/1/36
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Results
End-point mRNA expression of pro-inflammatory 
cytokines and intermediate filaments in human astrocytes
We used end-point PCR as a basic screening tool to vali-
date the expression of GFAP in primary human cultures of
astrocytes. In addition, TNF-α samples showed an
increase in IL-1β mRNA expression. GS mRNA expression
was constitutively expressed in astrocytes even after stim-
ulation with cytokines and QUIN (Figure 1A). Our data
also indicates that astrocytes constitutively expressed IL-6
and S100β (data not shown).
Real-time mRNA expression of pro-inflammatory 
cytokines and intermediate filaments in human astrocytes
We performed real-time PCR to quantitatively measure
the gene expression of selected genes including vimentin.
Real-time PCR results are shown in Figure 2 for Vimentin
(a) and (b), GFAP (c) and (d), IL-1β (e) and (f). Vimentin
mRNA levels were increased approximately 0.5 to 1-fold
by IFN-γ, TNF-α and TGF-α compared to untreated con-
trols. With the exception of QUIN 50 nM, VIM expression
was significantly increased by all doses of QUIN. At
pathophysiological concentrations QUIN 350, 500 and
1200 nM [4,27,28], VIM expression was respectively
increased by 13%, 38% and 40%. Similarly, GFAP expres-
sion was increased by cytokines IFN-γ and TGF-α but there
was no significant effect with TNF-α. GFAP expression was
increased respectively by 49% and 8% with physiological
(50 nM) and supra-physiological (150 nM) concentra-
tions of QUIN. In contrast to VIM expression, GFAP
expression was gradually reduced with increasing concen-
trations of QUIN. Treatment with pathophysiological
concentrations of QUIN 350, 500 and 1200 nM led
respectively to a 9%, 22% and 39% decrease in GFAP
expression. IL-1β expression was highest with TNF-α (pos-
itive controls). Both IFN-γ and TGF-α up regulated IL-1β
expression by 50% and 25%, respectively. IL-1β mRNA
reached their highest level of expression in astrocytes
treated with QUIN 350 nM but the levels gradually
decreased with higher QUIN doses. The levels of IL-1β
mRNA induction by QUIN 350 nM were comparable to
those induced by IFN-γ.
ELISA quantification of GFAP and vimentin protein levels 
in human astrocytes
GFAP and Vimentin sandwich ELISAs were performed in
triplicates (Figure 3). All samples except IFN-γ stimulated
Vimentin protein expression and QUIN 50 nM stimulated
GFAP expression (p < 0.05). There was an increase in
GFAP protein levels of 25%, 50% and 75% in samples
stimulated with cytokines IFN-γ, TNF-α and TGF-α,
respectively. In contrast to real-time PCR data (Figure 2),
all concentrations of QUIN except for 50 nM, led to dose-
dependent decrease in GFAP expression although GFAP
levels were markedly above untreated astrocytes. Similarly
with mRNA expression, production of GFAP protein was
dose dependently reduced with pathophysiological con-
centrations of QUIN. Production of VIM protein was
opposite to the expression of GFAP with a reduction of
5%, 35% and 55% in samples stimulated with IFN-γ, TNF-
(A) Ethidium bromide-stained gel showing mRNA expression of GS and GAPDH 24 hrs after cytokine or QUIN treatments Figure 1
(A) Ethidium bromide-stained gel showing mRNA expression of GS and GAPDH 24 hrs after cytokine or 
QUIN treatments. Results are expressed as a ratio of specific gene expression normalized against expression of the house-
keeping gene GAPDH. Standard errors were always 5%. (B) Glutamine synthetase activity after 24 hours stimulation with 
QUIN. GS enzyme assay has been done in triplicate (P < 0.05 was taken as significant).
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Expression of VIM, GFAP and IL-1β genes following 24 hours stimulation with cytokine/growth factor and QUIN Figure 2
Expression of VIM, GFAP and IL-1β genes following 24 hours stimulation with cytokine/growth factor and 
QUIN. Real-time PCR results for VIM (a and b), GFAP (c and d), IL-1β (e and f). Each experiment repeated, n = 3. A statistical 
value of P < 0.05 was taken as significant.Journal of Neuroinflammation 2009, 6:36 http://www.jneuroinflammation.com/content/6/1/36
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α and TGF-α, respectively. Treatments with physiological
(50 nM) and supra-physiological (150 nM) concentra-
tions of QUIN led to a 52% and 46% decrease in VIM pro-
duction respectively. However, with pathological
concentrations of QUIN (500 and 1200 nM) VIM protein
levels were significantly increased by 58% and 81%
respectively compared to untreated controls.
MTT cell viability/proliferation assay
Astrocytes were left to proliferate for 96 hours. The assay
was done in triplicate. The normal control (5% FCS) was
set to 100%. As seen in figure 4, TNF-α and samples
treated with QUIN 50 nM had no significant effect on
astrocyte proliferation. In contrast, IFN-γ had an increase
of nearly 10% in cell proliferation. A significant increase
in proliferation was observed for samples treated with
QUIN 150, 350 and 500 nM. Samples stimulated with
QUIN 1200 nM had approximately 10% reduction indi-
cating cell death/apoptosis.
GS enzyme activity
We found that treatment with QUIN led to a dose depend-
ent decrease in GS enzyme activity (Figure 1B). All sam-
ples excluding samples treated with QUIN 50 nM were
statistically significant (p < 0.05).
Discussion
Several studies have shown that the levels of the excito-
toxin QUIN can reach μM concentrations in the brain
parenchyma and CSF during neuroinflammation [4,29].
We previously showed that QUIN is toxic to human neu-
rons and astrocytes at concentrations as low as 100 nM
[30,31] and 350 nM [17]. We also previously demon-
strated that QUIN is able to activate both adult simian
and human foetal astrocytes to a similar extent leading to
production of inflammatory chemokines [15]. In the
present study, we assessed the effects of QUIN on the level
of expression of IL-1β and structural proteins GFAP and
VIM, on cell proliferation and on glutamine synthetase
activity in primary cultures of human astrocytes.
QUIN at submicromolar concentrations can produce neu-
rotoxicity in culture if maintained for several weeks and
neuronal apoptosis upon exposure to 100 nM QUIN [32].
We have chosen the concentrations of QUIN (50, 150,
350, 500 and 1200 nM) in accordance to the concentra-
tions used by previous studies [4,27,33,34]. For the pur-
pose of our study, it is important to use pure cultures of
astrocytes to maintain accuracy in measuring astrocytic
gene expression, proliferation and GS activity. Due to the
overlapping cytokine expression of microglia and astro-
cytes, our study utilizes only pure cultures of astrocytes to
avoid inaccurate quantitative measurement of pro-inflam-
matory cytokines induced by QUIN. Also, for proliferative
studies on astrocytes, it is crucial to use pure cultures of
astrocytes to accurately measure proliferation because
microglia have been shown to proliferate during activa-
tion as well. However, microglia activation and recruit-
ment but no proliferation was sufficient to mediate
neurodegeneration [35].
The cytokine IL-1β is known to play important roles in
both immune regulation and pathogenesis of AD [36].
Within the CNS, IL-1β is produced by astrocytes, micro-
glia and brain microvascular endothelial cells [37]. IL-1β
is known to be over-produced in AD brain and is associ-
ated with neuroinflammation, increased Aβ production,
deposition and plaque formation [38]. Using real-time
PCR, we found that at low concentrations QUIN induces
a dose dependent increase in IL-1β mRNA level and
would likely increase IL-1β production and secretion.
However, we could not detect any significant IL-1β pro-
duction in the culture supernatant using ELISA (data not
shown). There are several potential explanations for these
results. The first is that damaged astrocytes undergoing
necrosis release the inactive pro-forms of IL-1β whereas
apoptotic astroglial cells produce the mature form of IL-
1β [39]. We previously showed that only a small propor-
tion of astrocytes undergo apoptosis following treatment
with QUIN 500 and 1200 nM [40], therefore the level of
mature IL-1β produced and released is likely to be low and
under the level of detection. Secondly, other studies have
reported that co-culture of microglia activated with LPS, a
potent inducer of QUIN production, with astrocytes leads
to significantly higher astroglial IL-1β production com-
pared to cultures with inactivated microglia. These data
Quantification of GFAP and vimentin using ELISA after 24  hours stimulation with IFN-γ, TNF-α, TGF-α and QUIN Figure 3
Quantification of GFAP and vimentin using ELISA 
after 24 hours stimulation with IFN-γ, TNF-α, TGF-α 
and QUIN. GFAP and VIM indirect ELISA have been done 
in triplicates. All samples except IFN-γ stimulated VIM pro-
tein expression and 50 nM QUIN stimulated GFAP expres-
sion were statistically significant (p < 0.05).Journal of Neuroinflammation 2009, 6:36 http://www.jneuroinflammation.com/content/6/1/36
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suggest that microglial cells play a key role in IL-1β pro-
duction by astrocytes [11,41]. Interestingly, at low con-
centrations neither QUIN (80 and 120 nM) nor IL-1β (10
ng/μL) separately induced any neuronal damage, but in
combination lead to a significant loss of pyramidal neu-
rons in rat hippocampus [16]. This synergetic action is
likely to play a significant role in the neuropathogenesis
of AD, as both molecules are concomitantly present in the
AD brain.
Cytoskeleton re-organization is an important step of the
astroglial response to pathologic stimuli [42,43]. Astro-
cyte activation (astrogliosis) is characterized by changes in
co-existing intermediate filaments, particularly GFAP and
VIM, together with cellular hypertrophy and/or hyperpla-
sia [44]. In physiological conditions, human astrocytes in
the white matter are weakly immunoreactive for VIM but
in inflammatory areas in AD brain over-express VIM [45].
Our real-time PCR results (Figure 2a) show that IFN-γ,
TNF-α and TGF-α can significantly increase VIM mRNA
expression compared to untreated controls. Izmailova et
al. previously showed that IFN-γ also induces mRNA
expression of VIM in HeLa cells [46], which is in accord-
ance with our data. However, our ELISA results showed
that treatment with IFN-γ, TNF-α and TGF-α led to a
reduction in levels of VIM protein compared to untreated
controls. These results suggest that VIM expression is
likely to be regulated by post-transcriptional or post-trans-
lational mechanisms. Several other studies have shown
that TNF-α and TGF-α can activate murine astrocytes and
induce both VIM and GFAP over-expression [24,47,48].
TGF-α was included in the ELISAs as a positive control, as
it is known to induce GFAP expression and astrogliosis
[24]. We found that GFAP mRNA expression was signifi-
cantly increased by IFN-γ and TGF-α but not by TNF-α.
ELISA results showed that all three cytokines could induce
significant increase in GFAP. Previous studies have found
that IFN-γ can induce GFAP mRNA and protein expression
in both human and rodent primary astrocytes, which is in
accordance with our data [49]. We also found that treat-
ment with neuropathological concentrations of QUIN
(>150 nM) leads to a switch between structural protein
expressions in a dose dependant manner. QUIN increases
VIM and concomitantly decreases GFAP expression at
both mRNA and protein levels (Figures 2b and 3) com-
pared to untreated controls. The effect of QUIN is likely to
be mediated by the activation of NMDA receptors. Previ-
ous studies have shown that NMDA-induced excitotoxic-
ity resulted in increased VIM expression in rat astrocytes
[50,51]. Using calcium flux imaging, we recently demon-
strated that QUIN is able to activate human foetal astro-
cytes through functional glial type NMDA receptors (data
not shown). We have demonstrated that pathophysiolog-
ical concentrations of QUIN induce a substantial VIM/
GFAP cytoskeleton re-organization, known to be associ-
ated with hypertrophy and/or astrogliosis, in human pri-
mary astrocytes. The relevance of these data is that QUIN
induced-astrogliosis is likely to contribute to scar forma-
tion suppressing local axonal regeneration or neuronal
regrowth. Using knockout mice for VIM and/or GFAP,
Ribotta et al. have found a significant decrease in glial scar
formation associated with an increase in neuronal density
and neurite growth [52]. The glial scar is mostly com-
posed of reactive astrocytes (VIM+/GFAP+) and often
leads to failure in CNS regeneration [53].
Astrocyte proliferation (astrocytosis) is also a feature asso-
ciated with neuroinflammation [54]. Previous studies
have shown that inflammatory cytokines have the ability
to induce astrocytosis. Tejada-Berges et al. showed that
TNF-α could induce significant proliferation human pri-
mary adult astrocytes [55]. However, in that study astro-
cytes were grown in 15 to 30% FBS-containing medium
whereas in our study the culture medium used for the pro-
liferation assay was optimised at 5% serum (higher and
lower concentrations were also tested - data not shown).
In these conditions we did not observe any significant
effect of TNF-α on astroglial proliferation. Two other stud-
ies have also reported that TNF-α could induce prolifera-
tion in human and simian adult astrocytes [56,57]. These
discrepancies suggest a difference in TNF-α responsive-
ness between adult and foetal astrocytes. We then looked
at IFN-γ ability to induce astrocytosis and we found, in
accordance with previous studies, that this cytokine can
significantly increase astrocyte proliferation. IFN-γ
increases proliferation of human primary adult astrocytes
in 5% FBS-containing culture medium [55] and murine
neonatal astrocytes [47].
Finally, we assessed QUIN effect on astrocytosis. At low
levels (150 nM) QUIN induces a significant increase of
Proliferation measurement after stimulation with QUIN for  96 hours, SF = serum free, 5% FCS = normal control and  10% FCS = positive control Figure 4
Proliferation measurement after stimulation with 
QUIN for 96 hours, SF = serum free, 5% FCS = nor-
mal control and 10% FCS = positive control. Statistical 
values of P < 0.05 = *, P < 0.01 = ** and P < 0.001 = *** were 
taken as significant. Proliferation assay was optimized at 96 
hours and was done in triplicates. The normal control (5% 
FCS) was set to 0%.Journal of Neuroinflammation 2009, 6:36 http://www.jneuroinflammation.com/content/6/1/36
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GFAP and proliferation of human astrocytes emphasizing
that GFAP is a good marker for early stage astrocytosis.
Astrocyte proliferation peaked in samples treated with
pathophysiological concentration of QUIN (350) nM
with a 20% increase in proliferation. This is in accordance
with an earlier in vivo study showing that five days post-
injection with QUIN (240 nM) in rat striatum, a signifi-
cant increase in proliferation in GFAP-immunoreactive
astrocytes could be observed [58]. Moreover, Martinez-
Contreras et al have shown that glutamate-induced excito-
toxicity can also display an increase in astrocyte prolifera-
tion, increased mRNA and protein expression of GFAP
and VIM in rats [59]. At its highest pathological concentra-
tion QUIN (1200 nM) led to a significant reduction in cell
proliferation, which is likely to be associated with cell
death. We previously demonstrated that astrocytes were
undergoing apoptosis when treated with QUIN 500 and
1200 nM [17].
Neuronal activity leads to the production of glutamate,
which is then taken up and recycled by astrocytes [18].
Glutamine synthase (GS) is an enzyme playing a key role
in the regulation of the glutamate-glutamine cycle within
astrocytes. Decrease in GS activity has been previously
reported in AD pathogenesis [19]. Tavares et al have
shown that glutamate uptake by astrocytes is inhibited by
QUIN [60]. A number of studies involving rat astrocytes
and human gliomas have shown that changes in the gluta-
mate uptake correlate with changes in GS activity [61,62].
Our end-point PCR results showed that GS is constitu-
tively expressed even following QUIN or cytokine stimu-
lations (Figure 1A). However, our functional study
demonstrated that QUIN significantly inhibited GS activ-
ity in human foetal astrocytes in a dose dependent man-
ner (Figure 1B). This latter finding supports observations
from an earlier study showing that changes in GS activity
are occurring at the protein level [19]. Some studies have
shown that GS is sensitive to oxidative stress and free rad-
icals that may induce structural change to the enzyme and
leading to its inactivation [63,64]. Inhibition of GS activ-
ity by QUIN is likely that to be an indirect mechanism as
this excitotoxin is known to induce the formation of free
radicals [65]. Inhibition of GS by QUIN would lead to
accumulation of glutamate in the extracellular environ-
ment, with enhanced excitotoxicity leading to neuronal
death. Our data are in accordance with previous findings
showing that astrogliosis is inversely correlated with a
reduction in glutamine levels [7]. GS function is decreased
in AD-affected regions while QUIN levels are increased
[4,8] supporting further the involvement of QUIN in AD
neuropathogenesis.
All together, this study suggests that QUIN is likely to play
a key role in the complex neuropathogenesis of AD
through several inflammatory and/or cytotoxic mecha-
nisms. We showed that QUIN can induce IL-1β produc-
tion, astrogliosis and inhibit GS function. These findings
are likely to be relevant for the development of novel ther-
apies for AD [66] and for several other neuroinflamma-
tory diseases [2,67].
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